Organovo Holdings Inc  

(Public, NYSEMKT:ONVO)   Watch this stock  
Find more results for PINK:ONVO
2.81
+0.10 (3.69%)
May 27 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.65 - 2.83
52 week 1.60 - 5.82
Open 2.68
Vol / Avg. 0.00/409,831.00
Mkt cap 269.27M
P/E     -
Div/yield     -
EPS -0.43
Shares 92.41M
Beta 1.19
Inst. own 20%
Jun 9, 2016
Q4 2016 Organovo Holdings Inc Earnings Call - 5:00PM EDT - Add to calendar
Jun 9, 2016
Q4 2016 Organovo Holdings Inc Earnings Release Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -3187.50% -5268.30%
Operating margin -3192.07% -5305.95%
EBITD margin - -5223.20%
Return on average assets -53.69% -58.03%
Return on average equity -57.77% -62.04%
Employees 80 -
CDP Score - -

Address

6275 Nancy Ridge Drive Suite 110
SAN DIEGO, CA 92121
United States - Map
+1-858-5509994 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.